Watch on-demand now to learn about the insulin component of pet diabetes management and describe a novel compound that is effective in addressing both type 1 and type 2 diabetes.
Most people are aware of the alarming increase in the global prevalence of diabetes mellitus in humans, with current estimates of incidence lying somewhere between 450 and 500 million people. The two main types of diabetes in humans are type 1 or insulin-dependent diabetes, which only accounts for 5-10% of all cases, and type 2 or non-insulin-dependent diabetes mellitus (NIDDM), which is by far the most common.
Diabetes is also becoming an increasing health issue in dogs and cats with many of the etiological considerations for development (e.g. diet, obesity, age) being common between humans, dogs and cats. However, there is a clear division in the main types of diabetes predominating in cats and dogs. Diabetes in dogs is mainly of the type 1 variety, while in cats a pattern more akin to type 2 diabetes is evident. Regardless, the go-to treatment for clinical DM in dogs or cats is insulin combined with dietary modification.
This webinar will focus on the insulin component of pet diabetes management and describe a novel compound which is effective either as an injection or by oral administration and which can address both type 1 and type 2 diabetes. It achieves this by activating the insulin receptor even when insulin is absent and/or when a condition of insulin resistance prevails.
WHAT YOU’LL LEARN:
- Refresher on insulin signaling and types of diabetes in dogs and cats.
- Insulin receptor and activation of the insulin signaling cascade.
- Introducing an alternative to insulin which works as an oral or injectable for dogs and cats.
- Data supporting the efficacy of the new molecule in models of type 2 and type 1 diabetes.
This webinar is sponsored by Alltech and presented by Petfood Industry and WATT Global Media.
Dr. Ronan Power, vice president and chief scientific officer at Alltech
Dr. Ronan Power is vice president and chief scientific officer at Alltech. Since 2002, Dr. Power has been based at the Alltech Center for Animal Nutrigenomics and Applied Animal Nutrition in Nicholasville, Kentucky, USA. He maintains a broad range of research interests related to the application of Alltech products in animal nutrition and human health, with an emphasis on preventing syndromes and diseases associated with mitochondrial dysfunction and gastrointestinal stress. Dr. Power joined Alltech in 1991 as European director of research, initially based on the campus of the National University of Ireland, Galway, where he was an adjunct professor in the Department of Biochemistry. During this time, he also directed Alltech’s regulatory affairs division in Europe. In 1998, he re-established Alltech’s European Bioscience Centre at its new headquarters in Dunboyne, County Meath, Ireland, where he maintained an active graduate student program through which many Ph.D. and Master of Science candidates have successfully obtained their degrees. He received a bachelor’s degree in microbiology and a Ph.D. in biochemistry from the National University of Ireland. Afterward, Dr. Power completed his postdoctoral training in cell biology at Baylor College of Medicine in Houston, Texas, where he studied aspects of steroid hormone action in reproductive physiology and disease.